Shenzhen research team independently developed anti-neo-coronavirus recombinant protein

Since the new crown entered the world pandemic, a variety of new coronavirus mutant strains have appeared around the world, while three mutant strains (B1.1.7, 501Y. V2, P.1) because of its rapid spread and other possible characteristics (such as immune escape), has been highly concerned by researchers in various countries.
Recently, The Research Group of Zhong Guocai of Shenzhen Bay Laboratory found that ACE2-lg, a broad-spectrum anti-new coronavirus recombinant protein developed by the research group, can effectively inhibit a variety of mutant strains, including the above three mutant strains, and provide direct experimental evidence support for the further development of ACE2-lg broad-spectrum anti-new coronavirus candidates.
January 27, the Zhong Guocai Task Force of Shenzhen Bay Laboratory published the title "Lyning SARS-CoV-2 variants B.1.1.7, 501Y. V2, and P.1 have gainedability to utilize rat and mouse Ace2 and altered in vitro in vitro resy to neutralizing antibodies and ACE2-Ig" new coronavirus research paper.
the study tested seven new coronavirus mutant strains of the fake virus, three clinical stages of new coronary and antibodies, as well as Zhong Guocai task force independently developed broad-spectrum anti-neo-coronavirus recombinant protein ACE2-Ig, found the new corona B1.1.7, 501Y. V2 and P.1 mutant strains can use ACE2 as a subject in rats and mice, significantly reducing the virus's sensitivity to partial and antibodies, but not only did the neutral sensitivity of ACE2-Ig protein not decrease, but improved, the seven mutant strains tested were highly inhibited by ACE2-Ig.
since the new crown entered the pandemic, a variety of new coronavirus mutant strains have emerged around the world, making it particularly important and urgent to fully study the spread and immune sensitivity of these strains.
With this as the starting point, Zhong Guocai's team quickly studied 7 new coronavirus variant strains of false virus, 3 clinical stages of new coronary and antibodies, and Zhong Guocai's group independently developed broad-spectrum anti-neo-coronavirus protein ACE2-Ig, mainly obtained the following 3 aspects found: 1. Unlike early epidemic strains, recent mutations in the UK (B1.1.7), South Africa (501Y.V2) and Brazil (P.1) have acquired the ability to infect cells using ACE2 in rats and mice, suggesting that these mutants may have the ability to infect mice.
2. All mutations tested can impair the activity of more than one medium antibody; The South African 501Y.V2 mutant, the Brazilian P.1 mutant, and a water slug-related mutation in the Netherlands-Denmark have allowed Eli Lilly Clinical Phase III antibodies etesevimab (JS016) and Regeneron to be approved for listing antibodies. (REGN10933) the ability to suppress viral infection is partially or almost completely lost, in addition, on the basis of the otter-related Y453F mutation, if another nucleotide mutation causes the Q498H amino acid mutation, the regenerative meta company approved the listing of the "cocktail" therapy antibody casirivimab/REGN10933 and imdevimab/REGN10987 may fail at the same time (Figure 2).
coincidence, Lilly and Regeneration announced on the same day (January 27) the results of phase III clinical trials of etesevimab/JS016, casirivimab/REGN10933, and imdevimab/REGN10987 antibodies, respectively.
3. Not only did none of the seven mutations tested weaken the inhibitory activity of ACE2-Ig, but the IC90 of six of the mutations inhibited by ACE2-Ig increased by nearly 4.5-6 times;
, Zhong Guocai team members in this study found the current rapid spread of the United Kingdom, South Africa and Brazil virus mutant strains (B1.1.7, 501Y. V2, P.1) can use rats and mice ACE2 as a subject (suggesting cross-species transmission risk), and significantly reduce the sensitivity of the virus to parts and antibodies, making the outbreak prevention and control of mutant strains face greater challenges, fortunately, the neutral sensitivity of the ACE2-Ig protein developed by the task force has not decreased, but improved.
This research can provide direct experimental evidence support for the further development of ACE2-Ig candidate drugs for broad-spectrum anti-new coronavirus, and also provide an important scientific basis for scientific and technological anti-epidemic and the formulation of new coronavirus mutation prevention and control policies.
a number of foreign teams have also recently shared their findings on the UK and South African mutants via the preprinted site bioRxiv, which was published by Moderna on January 25th. The in-body introphy and activity of the mRNA vaccine (mRNA-1273) immunoserial serum decreased 5-10 times; V2 mutant strains have the ability to escape from the medium antibodies of multiple targeted RBD critical sequences.
These results are consistent with the findings of the Zhong Guocai Task Force, which has not been reported in other articles on the use of rat ACE2 as a subject and the increased sensitivity of each variant strain to ACE2-Ig.
study was mainly carried out by Dr. Li Yujun, Associate Researcher of Shenzhen Bay Experiment, and Dr. Yao Wei, Postdoctoral Fellow of Shenzhen Bay Laboratory/Shenzhen Graduate School of Peking University.
Yao Wei is the first author of this article, and other lead authors include Wang Yifei, research assistant of Shenzhen Bay Laboratory, Ma Danhui, Dr. Li Yujun and Dr. Zhong Guocai are co-authors of this paper.
study is also an important continuity work of Zhong Guocai's research on the risk of transsexual transmission in the new crown and the development direction of broad-spectrum anti-coronavirus candidate drugs.